DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Core Insights - DBV Technologies has successfully completed the patient screening for the VITESSE Phase 3 clinical trial, which evaluates the Viaskin® Peanut Patch in children aged 4 to 7 with peanut allergies [1][2] - The VITESSE trial is the largest immunotherapy clinical trial for this demographic, involving over 600 subjects across 86 sites in multiple countries [2] - Topline results from the VITESSE study are anticipated by Q4 2025 [1] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions [3] - The company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™), which aims to desensitize the immune system to allergens [3] - DBV is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for Viaskin Peanut targeting both toddlers and children [3] Operational Highlights - The VITESSE Phase 3 trial is a 12-month study designed to evaluate the efficacy and safety of the Viaskin Peanut Patch [2] - The trial has achieved enrollment ahead of schedule, closing screening a month earlier than expected [2] - DBV Technologies is headquartered in Châtillon, France, with operations in North America [4]